Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

被引：0
|
作者：
Ghosh, Nilanjan [1 ]
Sehgal, Alison R. [2 ]
Liu, Fei Fei [3 ]
Kostic, Ana [4 ]
Crotta, Alessandro [5 ]
Peng, Lily [4 ]
De Benedetti, Marc [3 ]
Gordon, Leo, I [6 ]
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Bristol Myers Squibb, Seattle, WA USA
[5] Celgene, Boudry, Switzerland
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
705
引用
收藏
页码：10430 / 10431
页数：2
相关论文
共 50 条
  • [1] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
    Deger, K.
    Oniangue-Ndza, C.
    Elsada, A.
    Litkiewicz, M.
    Villalobos, Franco C.
    Sorensen, S.
    VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
  • [2] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy S.
    Kamdar, Manali
    Liu, Fei Fei
    Crotta, Alessandro
    Previtali, Alessandro
    Klijn, Sven L.
    Wang, Pearl
    Situ, Aaron
    Zhang, Yixie
    Bonner, Ashley
    Lunning, Matthew A.
    BLOOD, 2022, 140 : 4655 - 4656
  • [3] Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Parker, Christopher
    Liu, Fei Fei
    Deger, Kristen
    Franco-Villalobos, Conrado
    Proskorovsky, Irina
    Keating, Scott J.
    Sorensen, Sonja
    Dorman, Emily
    BLOOD, 2021, 138
  • [4] Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.
    Sehgal, Alison
    Hoda, Daanish
    Riedell, Peter A.
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard
    Godwin, John E.
    Reagan, Patrick Michael
    Wagner-Johnston, Nina D.
    Essell, James
    Nath, Rajneesh
    Solomon, Scott R.
    Champion, Rebecca
    Licitra, Edward
    Fanning, Suzanne
    Gupta, Neel K.
    Dubowy, Ronald L.
    D'Andrea, Aleco
    Wang, Lei
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
    Sehgal, Alison R.
    Hildebrandt, Gerhard
    Ghosh, Nilanjan
    Godwin, John E.
    Wagner-Johnston, Nina D.
    Hoda, Daanish
    Licitra, Edward J.
    Munoz, Javier
    Trede, Nikolaus S.
    Wang, Lei
    Thorpe, Jerill
    Gordon, Leo, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.
    Gordon, Leo I.
    Hoda, Daanish
    Shi, Ling
    Guo, Shien
    Liu, Fei Fei
    Braverman, Julia
    Dubowy, Ronald L.
    Peng, Lily
    Sehgal, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Subgroup analyses of primary refractory vs early relapsed Large B-cell Lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs Standard of Care (SOC) as second-line (2L) therapy
    Glass, B.
    Nastoupil, L.
    Kamdar, M.
    Chavez, J. C.
    Ghesquieres, H.
    Ghosh, M.
    Holmes, H.
    Lopez-Guillermo, A.
    Martinez-Lopez, J.
    Novak, U.
    Ribrag, V
    Roddie, C.
    Waller, E. K.
    Feldman, T.
    Rosenthal, A. C.
    Sauter, C.
    von Bonin, M.
    Karmali, R.
    Montheard, S.
    Previtali, A.
    Abramson, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 210 - 211
  • [9] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Braverman, Julia
    Liu, Fei Fei
    Lanar, Sally
    Miera, Matthew
    Shah, Selam
    Devlen, Jennifer
    Salles, Gilles
    BLOOD, 2021, 138
  • [10] Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)
    Lunning, Matthew
    Deger, Kristen A.
    Liu, Fei Fei
    Elsada, Ahmed
    Klijn, Sven L.
    Litkiewicz, Michal
    Franco-Villalobos, Conrado
    Sorensen, Sonja V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S517 - S517
12345